MARKET

SEEL

SEEL

Seelos Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5000
-0.0300
-5.66%
After Hours: 0.5100 +0.01 +2.00% 16:44 03/27 EDT
OPEN
0.5000
PREV CLOSE
0.5300
HIGH
0.5202
LOW
0.4950
VOLUME
238.20K
TURNOVER
--
52 WEEK HIGH
3.940
52 WEEK LOW
0.4500
MARKET CAP
22.00M
P/E (TTM)
-0.1089
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SEEL and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SEEL stock price target is 6.00 with a high estimate of 8.00 and a low estimate of 4.000.

EPS

SEEL News

More
  • Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)
  • GlobeNewswire · 5d ago
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Seelos Therapeutics Announces Closing of Public Offering of Common Stock
  • GlobeNewswire · 03/16 21:30
  • The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
  • Benzinga · 03/13 11:52

Industry

Pharmaceuticals
-0.41%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About SEEL

Seelos Therapeutics, Inc., formerly Apricus Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The Company is engaged in developing its lead programs SLS-002 and SLS-006. The Company is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs), for the treatment of suicidality in post-traumatic stress disorder (PTSD), and in depressive disorder. SLS-006 is engaged in advancing their product candidate into late stage trials as a monotherapy in early stage Parkinson's disease patients, and as an adjunctive therapy with reduced doses of Levodapa (L-DOPA). SLS-007 is a peptide-based approach, targeting the nonamyloid component core (NACore).
More

Webull offers kinds of Seelos Therapeutics Inc stock information, including NASDAQ:SEEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SEEL stock news, and many more online research tools to help you make informed decisions.